Stribild is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Stribild should not be administered concomitantly with other medicinal products containing tenofovir disoprxil (as fumarate) used for the treatment of hepatitis B virus infection.
Stribild Summary of Product Characteristics, Gilead Sciences International Ltd, November 2021.

Stribild is a complete regimen for the treatment of HIV-1 infection; therefore, Stribild should not be administered with other antiretroviral medications for treatment of HIV-1 infection.
Stribild Prescribing Information, Gilead Sciences Inc, September 2021.

Viread should not be administered concomitantly with other medicinal products containing tenofovir disoproxil fumarate or tenofovir alafenamide.
Viread Summary of Product Characteristics, Gilead Sciences Ltd, September 2016.

Viread should not be used in combination with the fixed-dose combination product Stribild since tenofovir disoproxil fumarate is a component of this product.
Viread US Prescribing Information, Gilead Sciences Inc, February 2016.

Healthy volunteers (n=24) received elvitegravir/ritonavir (50/100 mg once daily) with or without tenofovir 300 mg once daily. Tenofovir and elvitegravir/ritonavir pharmacokinetics were not significantly affected by coadministration (tenofovir Cmax, AUC and Cmin increased by 1%,7% and 8% respectively; elvitegravir Cmax decreased by 2%, AUC increased by 2% and Cmin increased by 14%).
Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. Ramanathan S, Shen G, Cheng A, Kearney BP. J Acquir Immune Defic Syndr, 2007, 45(3):274-9.